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DOI: 10.1016/j.ajpath.2011.01.012This Month in AJPDo Circulating Tumor Cells Fare Better Alone
or in Clusters?
In epithelial-to-mesenchymal transition, cancer cells lose
cell-cell adhesion to facilitate metastasis; however, circu-
lating tumor microemboli (CTM) are also observed in
peripheral blood of metastatic cancer patients. Hou et al
(Am J Pathol 2011, 178:989–996) examined blood sam-
ples from advanced lung cancer patients to determine
whether cells within CTM have enhanced survival, and
thus metastasis, characteristics. The migration and inva-
sion marker vimentin was only expressed in some freely
circulating tumor cells but was present in most CTM cells
whereas E-cadherin expression was lost from CTM cells.
Cells within CTM did not display apoptotic features, but
some freely circulating tumor cells were apoptotic. These
results begin to distinguish CTM from single circulating tu-
mor cells, suggesting metastasis-promoting differences in
cells in peripheral blood.
At the Heart of Cancer Treatment
Cancer cachexia, which occurs in approximately 80% of
patients with advanced disease, is driven by proinflam-
matory cytokines that enhance NF-B signaling on mus-
cle cells. Wysong et al (Am J Pathol 2011, 178:1059–
1068) tested two novel drugs designed to specifically
inhibit NF-B by targeting the IB kinase (IKK) complex:
Compound A and NEMO binding domain (NBD) peptide.
Both Compound A and NBD were cardioprotective
against tumor-induced cardiac atrophy and systolic dys-
function in a mouse model of cancer cachexia. Com-
pound A did not affect tumor growth whereas NBD did,
though it had no effect on levels of circulating tumor-
derived cytokines. Thus, cardioprotective drugs that tar-
get the IKK complex may be valuable in preventing can-
cer cachexia-induced cardiac dysfunction.
Recipe for Corneal Nerve Regeneration
Even superficial corneal wounds can impair sensory
functions and reduce integrity of the corneal epithelium
when subbasalar nerves are damaged. To investigate the
role of acute inflammation in sensory nerve regeneration,
Li et al (Am J Pathol 2011, 178:1106–1116) used a
mouse model of corneal abrasion that removes the strat-ified epithelium and subbasal nerve plexus. On abrasion,
IL-17 CCR6  T cells as well as neutrophils and
platelets accumulated in the cornea followed by full res-
toration of the epithelium and partial regeneration of sen-
sory nerves.  T cells, neutrophils, and platelets were
each required for adequate nerve regeneration via a
mechanism involving VEGF-A, which is known to support
neurite growth. These data support a previously unrec-
ognized beneficial role for the  T cell-dependent inflam-
matory cascade (IL-17, neutrophils, platelets, and
VEGF-A) in corneal nerve regeneration.
Tumor-Associated Collagen Signature in
Breast Cancer
Stromal organization and function influences invasion
and metastasis of human breast tumors. Conklin et al
(Am J Pathol 2011, 178:1221–1232) examined the rela-
tionship between long-term survival and tumor-associ-
ated collagen signature (TACS)3, defined by bundles
of straightened and aligned collagen fibers perpendicu-
lar to the tumor boundary. Univariate statistical analysis of
second harmonic generation (SHG) imaging linked
TACS-3 with poor disease-specific and disease-free sur-
vival. Furthermore, TACS-3 was independent of tumor
grade and size, ER or PR status, HER-2 status, node
status, and tumor subtype. The strong statistical evi-
dence for poor survival in patients with TACS suggests
collagen alignment as a viable means for predicting
breast cancer survival.
ApoA-IV Deficiency Accelerates AD
Lipoproteins may influence Alzheimer’s disease (AD)
pathogenesis by affecting A deposition and clearance
in AD brain. Cui et al (Am J Pathol 2011, 178:1298–1308)
examined the role of the apolipoprotein A-IV (apoA-IV) in
accelerating AD pathogenesis in mice. In the APP/PS1
transgenic mouse mouse model of AD, knockdown of
ApoA-IV enhanced extracellular amyloid- peptide (A)
burden and aggravated neuron loss in the brain, resulting
in accelerated spatial learning deficits and increased
mortality. In vitro apoA-IV bound to A, and in vivo it
facilitated A clearance mediated by astrocytes. There-
fore, therapies that increase apoA-IV levels may be a
novel approach to treat AD patients.
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